Pioneering work from HUG and UNIGE for a safe EBOLA virus vaccine
Share this article
The team has successfully defined a “formula” capable of predicting the efficacy and safety of new Ebola virus vaccines.
By studying the plasma from 115 Genevan volunteers who took part in a clinical trial of a candidate virus in 2015, researchers observed that the concentration of five inflammation markers was sufficient to understand the gist of the immune response to the virus.
This promising formula is a practical and easy-to-use equation: addition of the concentrations of five substances whose activity is controlled by the monocytes – a category of white blood cells known for fighting the Ebola virus in the human body.